Press releases

August 13, 2020
Regulatory

Interim report for Q2 2020

Strong growth and earnings development in quarter affected by COVID-19

August 12, 2020

Health Canada provides COVID-19 Interim Order approval for Bactiguard’s endotracheal tubes

Health Canada has approved Bactiguard’s endotracheal tubes for infection prevention through an Interim Order. The approval is driven by COVID-19, as Bactiguard’s endotracheal tubes can reduce the risk of secondary infections for critically ill patients.

August 10, 2020

Invitation to the presentation of Bactiguard’s interim report on August 13, 2020

Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday August 13, 2020 at 7:30 CET.

June 03, 2020
Regulatory

Bactiguard initiates collaboration with online pharmacy Apotea on sales of Hydrocyn® aqua

Bactiguard initiates collaboration with the online pharmacy Apotea on sales of Hydrocyn® aqua (Hydrocyn) to consumers in the Swedish market. Recent tests confirm that Hydrocyn is the first disinfectant on the Swedish market with documentet effect on the new Corona virus causing COVID-19. Sales via Apotea will commence on 5 June.

June 02, 2020
Regulatory

Hydrocyn® aqua inactivates the coronavirus causing COVID-19

The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions.

May 29, 2020
Regulatory

Increased number of shares and votes in Bactiguard

During May 2020, the number of class B shares in Bactiguard Holding AB (publ) ("Bactiguard") has increased by 241,512. As a result, the total number of shares in the company as of May 29, 2020 amounted to 29,543,885 and the total number of votes to 69,543,885.

May 14, 2020

Bactiguard donates money to research on COVID-19

To contribute to the research on COVID-19, Bactiguard donates SEK 120,000 to Karolinska Institutet (KI) at Danderyd Hospital.

May 13, 2020
Regulatory

Interim report for Q1 2020

The development of the Covid-19 pandemic has painfully highlighted the urgent need for infection prevention. This has led to an increased interest in Bactiguard and generated strong sales from mid-March. Total revenues increased by more than 40 percent in the quarter and EBITDA doubled, generating an EBITDA margin of 30 percent and a positive net result.
May 13, 2020
Regulatory

Bactiguard appoints Gabriella Björknert Caracciolo as new CFO

Bactiguard Holding AB (publ) has appointed Gabriella Björknert Caracciolo, currently Head of Strategy, Development and Governance within Transaction Banking, Nordea as new CFO and Executive Vice President. She succeeds Cecilia Edström, who in February was appointed CEO of the company. Gabriella Björknert Caracciolo assumes her new position in August 2020.

May 07, 2020

Invitation to the presentation of Bactiguard’s interim report on May 13, 2020

Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Wednesday May 13, 2020 at 8:00 CET.

Pages